Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
Close

Search

Subscribe
3-year-old's metastatic cancer disappeared after two doses of experimental therapy
Health

3-year-old’s metastatic cancer disappeared after two doses of experimental therapy

Stephen Atcheler
By Stephen Atcheler
November 22, 2026 3 Min Read
Comments Off on 3-year-old’s metastatic cancer disappeared after two doses of experimental therapy

A promising breakthrough in cancer treatment has given a young boy a new chance at life.

Chimeric antigen receptor (CAR) T cell therapy is an immunotherapy technique that involves taking a patient’s immune cells and genetically modifying them to become powerful cancer-hunting predators.

The treatment has shown considerable promise in helping patients treat cancer, although its effectiveness has primarily been limited to treating blood cancers and not solid tumors.

But an inspiring real-life success story involving a three-year-old patient shows that scientists are also making great progress with CAR T cell therapy against solid tumors – and with potentially life-saving results.

In a report published in The New England Journal of Medicineresearchers document a case of complete regression of hepatoblastoma, a form of malignant liver cancer, in a 3-year-old boy after treatment with CAR T cells.

“This case demonstrates that a complete and durable response in a chemotherapy-resistant solid tumor can be achieved entirely in an outpatient setting without systemic toxicity,” says first author and pediatric oncologist David Steffin of Baylor College of Medicine in Houston, Texas.

When the boy was first diagnosed, he had a mass in the left lobe of his liver that measured 11.2 cm by 9.6 cm by 7.1 cm (4.4 × 3.8 × 2.8 inches).

3-year-old's metastatic cancer disappeared after two doses of experimental therapy

CT images showing the tumor shrinking after treatment. (Steffin et al., NEJM2026)

The cancer had metastasized to his lungs, and it appeared it had also spread to his bones.

The boy received three sessions of chemotherapy and his primary liver tumor was surgically removed, as well as two operations to remove the cancer that had spread to his lungs.

Despite the interventions, the cancer quickly returned, with the appearance of a new tumor in his lungs.

After this rapid recurrence, the boy was enrolled in the CARE study, the first human trial of an experimental form of CAR T cell therapy.

YouTube Thumbnail

The boy received two infusions of the experimental treatment GPC3-CAR, made from his own T cells but designed to recognize glypican-3 (GPC3), a protein highly expressed in liver cancers.

The researchers also designed the therapy to include genes that would express the immune proteins interleukin-15 and interleukin-21, to increase the longevity and tumor-killing capacity of CAR T cells, based on previous evidence from preclinical models.

After the first infusion, the patient had a partial response, indicated by CT scans and a drop in levels of a protein called alpha-fetoprotein in his blood, indicating tumor activity.

Eight weeks later, he received a second dose of treatment and follow-up exams showed no residual signs of the disease, except for some residual scarring.

After 12 months, the boy was still disease-free – an incredible outcome and turnaround for the patient and his family, considering the severity of his illness before his participation in the trial.

“This study provides evidence that these novel CAR T cells may be a safe and effective modality for hepatoblastoma and highlights the need for further evaluation in patients with GPC3+ solid tumors,” says co-author and pediatric oncologist Andras Heczey of Seattle Children’s Hospital and the University of Washington.

As the researchers note, liver cancer is the third leading cause of cancer death worldwide. Progress in this branch of immunotherapy treatments is therefore extremely promising, especially since this experimental CAR T cell therapy produced remission in a patient with a solid tumor.

Related: Woman with 3 autoimmune diseases went into remission after immune ‘reset’

Of course, it’s worth emphasizing that this is just one report from one patient in an early-phase trial, and we’ll have to see how other patients respond to GPC3-CAR treatment before researchers know how effective and safe it is.

Continuing testing is underway in the CARE study (at Baylor College of Medicine) and in a similar clinical trial called IMPACT, led by Seattle Children’s Hospital.

The hope is that over time we will see more positive results like this.

For now, we are off to a very promising start.

The results are reported in The New England Journal of Medicine.

ScienceAlert stories are written, fact-checked and edited by humans, never generated by AI. Don’t miss any stories, subscribe here.

Related news

Gn Health

Views: 4
Stephen Atcheler
Author

Stephen Atcheler

**Stephen** is a staff journalist at **DailyVoxa**, specializing in business, finance, technology, artificial intelligence, and global markets. He is committed to delivering timely, accurate, and insightful reporting that helps readers understand the forces shaping the global economy and the rapidly evolving digital landscape.Drawing on in-depth research and credible sources, Stephen covers breaking developments, industry trends, and emerging innovations with a focus on clarity, balance, and factual accuracy. His reporting is designed to provide readers with reliable information, practical context, and thoughtful analysis without sensationalism.As a member of the DailyVoxa editorial team, Stephen follows the publication's Editorial Policy, Fact-Checking Policy, Corrections Policy, and Ethics Policy. Every article is carefully reviewed to ensure it meets the highest standards of journalistic integrity, transparency, and editorial independence.

Follow Me
Other Articles
Major storm will bring winds and rain to the East Coast before Thanksgiving
Previous

Major storm will bring winds and rain to the East Coast before Thanksgiving

Estonia-Russia border closure has residents rushing to cross before deadline
Next

Estonia-Russia border closure has residents rushing to cross before deadline

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.
  • About Us
  • Accessibility Statement
  • Advertise With Us
  • AI Usage & Transparency Policy
  • Contact us
  • Cookie Policy
  • Corrections Policy
  • Meet Our Team
  • Privacy Policy
    • Disclaimer
    • DMCA & Copyright Policy
    • Editorial Policy
    • Ethics Policy
    • Fact-Checking Policy
  • Terms and Conditions
Copyright 2026 — Today's News. Tomorrow's Perspective.. All rights reserved.